Novo Nordisk A/S’s Wegovy (semaglutide) and Eli Lilly and Company’s Mounjaro (tirzepatide) are just the start of a promising new obesity market and, while those drugs have demonstrated impressive weight loss, drug developers are already turning their attention to the next generation of obesity medicines and how to address remaining unmet needs.
The Next Frontier In Obesity: Better, Not More, Weight Loss
R&D leaders from Novo Nordisk, Lilly, Boehringer Ingelheim and others discussed what some of the advances could be in the next generation of obesity medicines.
More from Alimentary/Metabolic
More from Therapy Areas
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.